Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.62 |
| ▸ | PREP | P48147 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534609 | 1.00 | DPP4 (0.67) | DPP4DPP8DPP9PREP | |
| Hydrochloric Acid SCHEMBL6703910 | 0.88 | DPP4 (0.66) | DPP4DPP8DPP9PREP | |
| SCHEMBL4893396 | 0.86 | DPP4 (0.57) | DPP4DPP8DPP9PREP | |
| SCHEMBL7337954 | 0.86 | DPP4 (0.65) | DPP4DPP8DPP9PREP | |
| SCHEMBL7337946 | 0.86 | DPP4 (0.65) | DPP4DPP8DPP9PREP | |
| SCHEMBL648663 | 0.82 | DPP4 (0.60) | DPP4DPP9 | |
| SCHEMBL3807494 | 0.82 | DPP4 (0.65) | DPP4DPP8DPP9PREP | |
| SCHEMBL3807500 | 0.82 | DPP4 (0.65) | DPP4DPP8DPP9PREP | |
| SCHEMBL1379249 | 0.82 | DPP4 (0.60) | DPP4DPP9 | |
| Hydrochloric Acid SCHEMBL6699813 | 0.81 | DPP4 (0.59) | DPP4DPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.